Challenges & Opportunities Facing Medical Device Market – The future of MedTech

The future of Medical Device Industry 2022

The evolution of the medical device industry has seen substantial growth in recent years and has faced many obstacles along the way. Advancements in IoT and AI continue to change the healthcare game bringing forth more capabilities and competition within the MedTech space. One thing is for sure, even through challenges, the medical device market will continue to evolve and transform the landscape of healthcare whether your business is ready for it or not.

2022 left businesses scrambling to adapt and meet the technological needs for medical device development and digital health during a pandemic. This impact left many at a crossroads between overcoming obstacles and capitalizing on new opportunities.

Current Challenges Faced by the MedTech Industry

MedTech Cyber Threats

As technology advances in the health tech world, the need for more cybersecurity increases. As we saw in 2017, when the National Healthcare Services UK experienced a cyber attack disabling healthcare computer systems around the country, cyber threats continue to circulate concern. Cyber threats pose a serious challenge for medical device companies making it imperative to have the proper security. How do you proceed to stay ahead of your competitors, offering value to patients while ensuring their personal information is safe? A proactive approach starting with the right design and the right team of experts is crucial. Implementing secure platforms will promise patients and MedTech companies a brighter, safer future.

MedTech Regulation Challenges

If you are unfamiliar with MedTech and digital healthcare regulations, don’t approach this complex world alone. Safety and quality are of the utmost importance for patients and for a MedTech company to thrive. The FDA requires specific criteria and regulations for software as a medical device and or bringing other products to the market. Without understanding the nuances of regulations, MedTech products may fail to be compliant, and you may end up spending a pretty penny. Bringing in the experts to help navigate compliance and regulatory complexities allows for a more seamless and effective process. Star’s HealthTech Practice has significant experience in compliant medical device development with a deep understanding of regulatory requirements and the importance of time and budget.

Opportunities in the Medical Device Market in 2022

With the rapid pace of technology and the need for more innovation, there will always be challenges. However, there has never been a better time to take advantage of this opportunity. The MedTech industry can positively impact healthcare by providing better technology that adds value. Offering products that implement data-driven capabilities to offer better communication between patient and provider will have a lasting positive impact on the healthcare sector.

There is still much room for improvement even with new technological advancements. It’s one thing to gather data, but it’s another to actually use this data for good to develop new healthcare solutions. This is where Star’s HealthTech Practice understands precisely how to implement proven platforms and systems to gain the proper knowledge and offer immense value with data technology.

Whether you’re a startup company or a legacy enterprise, the time is now to refine your approach and stay ahead of the ever-changing digital health technologies. What are your goals for 2022? Better yet, what are your goals for the future beyond 2022? If you’re ready to meet these challenges head-on and seize the opportunity, partnering with a team of leaders in the MedTech space is your next move. Star offers product strategy, a clear roadmap, expertise in software innovation, where communication and an aligned vision are critical for success. Start the new year with a solid foundation for your business and, most importantly, deliver value.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”